Ionis Pharmaceuticals (IONS) Leerink Global Healthcare Conference 2026 summary

Key product launches and market strategy

• Achieved priority review for TRYNGOLZA, with a pivotal year ahead and a June 30 PDUFA date for SHTG launch.

• FCS launch generated $108 million in 2025, exceeding expectations and showing strong patient access and payer engagement.

• SHTG targets a broader population (over 3 million in the US), with initial focus on high-risk patients (about 1 million) at risk for acute pancreatitis.

• Facing pricing pressure from a new competitor in FCS, but maintaining strong adherence and negotiating with payers for SHTG pricing.

• Peak US sales estimate for TRYNGOLZA and SHTG increased to over $2 billion based on HCP demand and payer research.

Competitive landscape and differentiation

• First-mover advantage in SHTG expected to last at least a year, with focus on high-risk patients for initial uptake.

• Once-monthly auto-injector administration seen as highly convenient, with no significant advantage for competitors' less frequent dosing.

• Product profile highlighted by 85% reduction in acute pancreatitis and 72% reduction in triglycerides, setting a high efficacy bar.

• Addressing hepatic fat fraction increases as an on-target, non-toxic effect, with long-term data showing return to baseline.

International commercialization and partnerships

• US focus for independent launches, with ex-US commercialization through partners; TRYNGOLZA launched in Europe with Sobi.

• Sobi targets the most severe ex-US patient population (triglycerides 880+), supporting higher pricing and a >$1 billion opportunity in Europe.

• Royalties from ex-US sales are in the mid-20% range.